We’re on a mission…
Q-Metrx provides quality controlled services for electrophysiological data collection, quantitative analysis, data management, statistical analysis, and publication of findings.
With the aid of the pharmaco-EEG, essential information can be obtained in early drug development regarding CNS penetration and efficacy of new substances as follows:
- Evidence for substance penetration (bioavailability) in the CNS on the basis of PD changes. In addition to the classic PK parameters (e.g., tmax, Cmax, AUC and t½), EEG/ERP parameters can be used to demonstrate time- and dose-effect correlations.
- Proof of CNS effects of a substance by comparison of quantitative EEG (qEEG/ERP) changes between pre- and post-dose measurements.
- Characterization of psychotropic properties of a substance by comparison with psychotropic class effects of marketed drugs. Classic psychotropic drugs show typical pharmaco-EEG profiles, thus allowing assignment of new substances in many cases.
- Determination of new substance’s therapeutic window. The dose at which a new substance can be statistically distinguished from placebo, and at which it displays a psychotropic effect in comparison with a reference preparation, is often a therapeutically effective dose.
- Proof of adverse CNS effects of non-psychotropic substances (e.g., sedation produced by anti-hypertensive drugs or anti-histamines, changed convulsion threshold due to antibiotics).
- Determination of the bioequivalence of two different galenic dosage forms by quantitative comparison of CNS changes.
- Healthy Normal Volunteers
As well as people suffering from:
- Major Depressive Disorder
- Essential Tremor
- Sleep Apnea
- Periodic Limb Movement Syndrome/Disorder (PLMS/D)
- Restless Legs Syndrome (RLS)
Q-Metrx has clinical trial experience with drugs and medical devices for the treatment of various conditions.
EEG and qEEG Course is now available ON-DEMAND. Learn at home at your own pace. Continuing education credit available.
We actively carry out research and publish on topics in clinical neuroscience and psychology.
Ereshefsky et al.
Nations et al.
Shambroom et al.
Johnstone et al.
A ThrA Three-Stage Neuropsychological Model of Neurofeedback: Historical Perspectives
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients
Use of Databases in QEEG Evaluation
Clinical Experience with Quantitative Electroencephalogram in Mild Head Injury